

Cumulative Compound Index

September 2004—August 2005

[Volume 47, Part 10—Volume 48, Part 9 *inclusive*]

Compound	Year	Vol	Part	Pages
A				
(+)-Abscisic acid, [4,5,8',8'-H-2(5)], 1- <i>O</i> - β -D-glucopyranoside	2005	48	6	435–445
<i>N</i> -([1-C-14]-Acetyl-([O-18(2)]-PO ₂)-cytidine monophosphate neuraminic acid	2004	47	14	1007–1017
3-Acetyl-2,2-dimethylcyclobutylacetaldehyde, [1-C-13]	2005	48	3	223–229
6-Acrylamido-4-(2-fluoroanilino)quinazoline, [F-18]	2005	48	2	109–115
<i>N</i> -(<i>IZ</i>)-2-Amino-1-aza-3-chloro-([2,3-C-13(2)]propenyl)-methoxycarboxamide, [N-15(3)]	2004	47	12	837–846
2-Amino- <i>N</i> -1-[2,3,4,5,6-H-2(5)]benzyl-2-hydroxy-3-[isobutyl-(4-nitrobenzenesulfonyl)amino]-propyl-3,3-dimethylbutyramide	2004	47	12	821–835
4,4'-bis-(3-Aminobutane-1-sulfonic acid) disulfide, [H-3(1)]	2004	47	13	997–1005
2-Amino- <i>N</i> -cyclohexyl- <i>N</i> -methylbenzamide, [3,5-H-3(2)]	2005	48	6	429–434
2-Amino-4,6-dichloropyrimidine, [4-C-14] or [2-N-15]	2005	48	6	397–406
2-Amino-1,9-dihydro-9-[(<i>1S,3R,4S</i>)-2-methylene-4-(phenylmethoxy)methyl]cyclopentyl-6 <i>H</i> -purin-6-one, [8-C-14]	2005	48	9	645–655
<i>N</i> -[2-Amino-3-hydroxy-3-(1-methylpiperidin-4-yl)-3 <i>H</i> -pyrrolo[3,2- <i>b</i>]pyridin-5-yl]propionamide, [2-C-14]	2005	48	9	669–681
7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-[C-14]carboxylic acid	2004	47	11	779–786
Amprenavir, [<i>ring</i> -H-2(5)]	2005	48	3	179–193
4-Aminotoluene, [methyl-C-11], <i>N</i> -ethanoyl (<i>p</i> -acetotoluidide, [C-11])	2005	48	9	629–634
Anilines, benzylamines and nitrogen heterocycles, [H-2] or [H-3] labelling of, Ir-catalysed	2005	48	1	75–84
Aprepitant, [C-14] and [C-13(1); N-15(3)]	2004	47	12	837–846
Aryl ketones, <i>ortho</i> -deuteration of, Ir-catalysed	2005	48	5	317–322
Avermectin B _{1a} and B _{1b} , [23-C-14]	2005	48	1	25–30
<i>N</i> -1-([N-15]-Aza)-3-oxo-2,3-diphenylprop-1-enyl-methoxycarboxamide	2004	47	12	837–846

Compound	Year	Vol	Part	Pages
B				
Benzil hydrazone, [N-15(2)]	2004	47	12	837–846
Benzylamines, [H-2] or [H-3] labelling of, Ir-catalysed	2005	48	1	75–84
4 <i>S</i> -Benzyl-3-2 <i>S</i> -[2,3,4,5,6- <i>H</i> -2(5)]benzyl-4-benzyloxy-3 <i>S</i> -hydroxybutyryl)-oxazolidin-2-one	2004	47	12	821–835
2 <i>S</i> -[2,3,4,5,6- <i>H</i> -2(5)]Benzyl-4-benzyloxy-3 <i>S</i> -hydroxybutyric acid	2004	47	12	821–835
4 <i>S</i> -[2,3,4,5,6- <i>H</i> -2(5)]Benzyl-4-(benzyloxymethyl)-oxazolidin-2-one	2004	47	12	821–835
1-1-[2,3,4,5,6- <i>H</i> -2(5)]Benzyl-2-hydroxy-3-[isobutyl-(4-nitrobenzenesulfonyl)-amino]propylcarbamoyle-2,2-dimethylpropylcarbamoylemethyl[(3-fluorobenzyl)carbamic acid, <i>tert</i> -butyl ester	2004	47	12	821–835
4 <i>S</i> -Benzyl-3-(3-[2,3,4,5,6- <i>H</i> -2(5)]phenylpropionyl)-oxazolidin-2-one	2004	47	12	821–835
4-Biphenylpropan-1,2-dione, aliphatic [H-2] and [H-3] exchange	2004	47	12	881–889
BILN2061, [H-2(7)], [H-3(1)] or [C-14(1)]	2005	48	6	447–455
BIRB 796, [H-2], [H-3], or [C-14]-labelled	2004	47	12	847–856
Bleomycin, [H-2]	2004	47	11	733–740
BMS-232632, [C-13(6)] <i>also Reyataz</i>	2005	48	2	123–130
Bromhexine, [H-3(2)]	2005	48	6	429–434
[Br-76] labelling of <i>closo</i> -iodocboranes by halogen exchange	2005	48	3	195–202
2-Bromobenzylamine, [3,4,5,6- <i>H</i> -2(4)]	2005	48	3	171–177
(5 <i>Z</i>)-4-Bromo-5-(bromomethylene)-2(5 <i>H</i>)-[2-C-14]furanone	2004	47	10	627–634
Bromo- <i>closo</i> -carboranes, [Br-76], all four isomers	2005	48	3	195–202
4-Bromofluorobenzene, [2,3,5,6- <i>H</i> -2(4)]	2005	48	6	421–427
5-([C-14]Bromomethyl)-benzo-1,3-dioxazole	2005	48		
2-Bromotoluene, [methyl-C-11]	2005	48	9	629–634
<i>cis</i> -2-Butene-1,4-diol, [1,2,3,4-C-13(4)]	2005	48	2	117–121
1-(5- <i>tert</i> -Butyl-2-(4-methylphenyl)-2 <i>H</i> -pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalene-1-yl]urea, [H-2(8)], [H-3(1)] or [C-14(1)]	2004	47	12	847–856
(<i>S</i>)-1'-((<i>N</i> - <i>tert</i> -Butyloxycarbonyl)amino)-1-([2,3,4,5,6- <i>H</i> -2(5)]-benzyl)-3-(benzyloxy)propan-2 <i>S</i> -ol	2004	47	12	821–835
(<i>S</i>)-1'-((<i>N</i> - <i>tert</i> -Butyloxycarbonyl)amino)-1-([2,3,4,5,6- <i>H</i> -2(5)]-benzyl)-propan-2 <i>S</i> ,3-diol	2004	47	12	821–835
[(<i>S</i>)-1'-((<i>N</i> - <i>tert</i> -Butyloxycarbonyl)amino)-2 <i>S</i> -([2,3,4,5,6- <i>H</i> -2(5)]-phenylethyl)oxirane	2004	47	12	821–835
2-Butyne-1,4-diol, [1,2,3,4-C-13(4)]	2005	48	2	117–121
C				
Caffeic acid, [C-13] labelled	2004	47	11	797–806
Caproic acid, [1-C-13]	2004	47	10	719–722
<i>N</i> -([1-C-13]-Caproyl)- <i>N</i> -phenylthiourea	2004	47	10	719–722
CEP-1347, [H-3]	2005	48	5	323–330
β -CFT-FP, [3-F-18(1)]	2005	48	6	463–471

Compound	Year	Vol	Part	Pages
Chloroacetonitrile, [C-13(2); N-15(1)]	2004	47	12	837–846
6-Chloro-3-((2 <i>S</i> -azetidiny)methoxy)-5-(2-fluoropyridin-4-yl)pyridine, [F-18]	2004	47	13	947–952
7-Chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-[C-14]carboxylic acid	2004	47	11	779–786
7-Chloro-4- <i>N</i> -[2-(<i>N,N</i> -dimethylaminomethyl)-1-ferrocenylmethyl]aminoquinoline, [3-C-14(1)]	2004	47	14	1019–1027
2-[(2-Chloroethyl)-(2'-fluoroethyl)amino]-2 <i>H</i> -1,3,2-oxazaphosphorinane-2-oxide, [F-18]	2005	48	9	635–643
4-Chloro-5-(imidazolidin-2-ylidenimino)-6-methoxy-2-methyl-[2,4,6-C-14(3)]-pyrimidine, <i>also</i> Moxonidine	2004	47	10	699–704
2-Chloroiminazo[1,2- <i>a</i>]pyridine, [C-14]	2005	48	6	397–406
<i>N</i> -[(2-C-14)-6-Chloro-9 <i>H</i> -pyrido[3,4- <i>b</i>]indol-8-yl)-3-pyridinecarboxamide	2005	48	5	323–330
3-Chloro- <i>L</i> -tyrosine, [Ar-C-13(6)]	2004	47	13	935–945
<i>trans</i> -Cinnamic acid, [C-13] labelled at C-2 and/or C-3	2004	47	12	895–901
Coumaric acid, [C-13] labelled	2004	47	11	797–806
<i>N</i> -2-[3-(2-Cyanophenoxy)-2-(methoxy[C-11])-propylamino]-ethyl- <i>N'</i> -(4-methoxyphenyl)-urea	2005	48	10	721–733
Cycloocta-1,5-dienyliridium(I)-1,1,1,5,5,5 hexafluoropentan-2,4-dionate in [H-2] and [H-3] labelling	2005	48	1	75–84
(1 <i>S</i> ,4 <i>R</i> ,6 <i>S</i> ,7 <i>Z</i> ,14 <i>S</i> ,18 <i>R</i>)-14-Cyclopentylloxycarbonylamino-18-[2-(2-isopropylamino-thiazol-4-yl)-7-methoxyquinolin-4-yloxy]-2,15-dioxo-3,16-diazatricyclo[14.3.0.0 ^{4,6}]nonadec-7-ene-4-carboxylic acid, [H-2], [H-3], or [C-14]	2005	48	6	447–455
3-Cyclopropylamino-2-(2,6-dichloro-5-fluoropyridine-3-carbonyl)-2-[C-14]acrylic acid	2004	47	11	779–786

D

Deramciclane, [H-3]	2005	48	9	693–700
Deuteration of enol acetates from aryl alkyl ketones	2005	48	5	337–352
<i>ortho</i> -Deuteration of aryl ketones, Ir-catalysed	2005	48	5	317–322
Deuterium exchange in C ₆ H ₅ X, Ir-mediated, ligand effects	2004	47	1	1–10
<i>O</i> -(2-Deoxy-2-fluoro-D-glucopyranosyl)- <i>L</i> -serine, [F-18]	2005	48	10	701–719
<i>O</i> -(2-Deoxy-2-fluoro-D-glucopyranosyl)- <i>L</i> -threonine, [F-18]	2005	48	10	701–719
4-[2-{4-[(1 <i>IR</i>)-3,10-Dibromo-8-chloro-6,11-dihydro-5 <i>H</i> -benzo[5,6]cyclohepta[<i>b</i>]pyridin-11-yl]-4-piperidyl}2-oxoethyl]-1-piperidinecarboxamide <i>also</i> <i>Sch</i> 66336, [C-13(2), N-15(1)]	2005	48	1	11–23
4-[2-{4-[(1 <i>IR</i>)-3,10-Dibromo-8-chloro-6,11-dihydro-5 <i>H</i> -benzo[5,6]cyclohepta[<i>b</i>]pyridin-11-yl] ([2,6- <i>H</i> -3]-4-piperidyl)-2-oxoethyl]-1-piperidinecarboxamide <i>also</i> <i>Sch</i> 66336	2005	48	1	11–23

Compound	Year	Vol	Part	Pages
(1 <i>R</i>)-3,10-Dibromo-8-chloro-11-([2,6-H-3]-4-piperidyl)-6,11-dihydro-5 <i>H</i> -benzo[5,6]cyclohepta[<i>b</i>]pyridine	2005	48	1	11–23
3,5-Dibromolaevalinic acid, [1-C-14]	2004	47	10	627–634
4,6-Dichloro-5-(1-acetylimidazolidin-2-ylidenimino)-2-methyl-[2,4,6-C-14(3)]-pyrimidine	2004	47	10	699–704
3,5-Dichlorobenzylamine, [1,2,3,4,5,6,7-C-13(7)]	2004	47	12	869–874
<i>N</i> -(3,5-Dichlorobenzyl)-4-([F-18, H-2(2)]fluoromethoxy)-benzenecarboximidamide	2005	48	1	1–10
<i>N</i> -([7-H-3]3,5-Dichlorobenzyl)-4-(fluoromethoxy)benzenecarboximidamide	2005	48	1	1–10
<i>cis</i> -1,2-Dichloroethylene, [1,2-C-14(2)]	2005	48	5	353–357
3-(2,6-Dichloro-5-fluoropyridine-3-yl)-3-oxo-2-[C-14]-propionic acid	2004	47	11	779–786
4,6-Dichloro-2-methyl-5-amino-[2,4,6-C-14(3)]-pyrimidine	2004	47	10	699–704
4,6-Dichloro-2-methyl-5-nitro-[2,4,6-C-14(3)]-pyrimidine	2004	47	10	699–704
4,7-Dichloroquinoline, [3-C-14(1)] or [4-C-14(1)]	2004	47	14	1019–1027
3,5-Dichloro- <i>L</i> -tyrosine, [Ar-C-13(6)]	2004	47	13	935–945
Diethyl acetylsuccinate, [1-C-14]	2004	47	10	627–634
<i>R</i> -2-{4-(3,5-Difluorobenzoylamino)phenyl}-1-(2-propanesulfonamido)-propane, [3-C-14(1)] or [3-H-3]	2005	48	2	85–100
2,4-Dihydroxy-2'-(4''-hydroxyphenyl)-([Ar-C-14(2)]-acetophenone	2004	47	11	741–752
4,6-Dihydroxy-2-methyl-5-nitro-[2,4,6-C-14(3)]-pyrimidine	2004	47	10	699–704
4,6-Dihydroxy-2-methyl-[2,4,6-C-14(3)]-pyrimidine	2004	47	10	699–704
[2-(3,4-Dihydro-1 <i>H</i> -isoquinolin-2-yl)pyridin-4-yl]-([C-11]dimethyl)amine	2004	47	13	911–920
(-)-Dihydrophaseic acid, [7'-H-2(3)]	2005	48	6	435–445
4-([1-C-11(1)]-1,3-Dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-[1,5- <i>a</i>][pyrazolo-1,3,5-triazine]	2004	47	13	971–976
<i>1R,2S,4R</i> -(-)-[2-H-3(1)]-2-(Dimethylamino)ethoxy-2-phenyl-1,7,7-trimethylbicyclo[2.2.1]heptane	2005	48	9	693–700
<i>1R,2S,4R</i> -(-)-2-(Dimethylamino)ethoxy-2-phenyl-1,7,7-trimethylbicyclo[2.2.1]heptane, [3-H-3(1)]	2005	48	9	693–700
4,8-Dimethyldecanal, [1-H-2(1)] and [10-H-2(3)]	2004	47	13	921–934
(<i>1S</i>)-(2,2-Dimethyl-8,8a-dihydro-3a <i>H</i> -indeno-[1,2- <i>d</i>]-oxazol-3- <i>R</i> -yl)-2-oxiranylmethyl-3-([ring-H-2(5)]phenyl)-propan-1-one	2005	48	3	179–193
<i>bis</i> -1-(2,2-Dimethylpropyloxysulfonyl)-3-amino-4-butyl disulfide, [H-3(1)]	2004	47	13	997–1005
<i>S</i> -(Dipropylamino)-6-iodo-1,3,4,5-tetrahydrobenzo[<i>cd</i>]indol-4-ylamine, [I-125]	2005	48	2	139–148
(-)-4- <i>S</i> -(Dipropylamino)-1,3,4,5-tetrahydrobenz[<i>cd</i>]indole-6-carboxamide, [carbonyl-C-14]	2005	48	2	139–148

Compound	Year	Vol	Part	Pages
(2 <i>S</i>)-Dipropyl {(8-[5-C-14(1)]isoxazol-5-yl)-1,2,3,4-tetrahydronaphthalen-2-yl}amine	2005	48	2	149–164
[<i>N</i> -[2-[[3-(3,3-Diphosphonopropylcarbonyl)propyl](2-thioethyl)amino]acetyl]-2-aminoethanethiolate] oxorhenium(V), [Re-186]	2004	47	11	753–761
Docetaxel, [C-11]	2004	47	11	763–777
L-DOPA, [3 <i>S</i> -H-3(1)] or [5'-H-3(1)]	2005	48	3	235–240
DPH-140662, [H-2(5)]	2004	47	12	821–835
DPH-153893, [H-2(5)]	2004	47	12	821–835
E				
Entecavir, [C-14]	2005	48	9	645–655
Ethyl iodide, [1-C-11] and [1-C-13]	2004	47	11	723–731
2-(Ethylsulfonyl)imidazo[1,2- <i>a</i>]pyridine-3-sulfonamide, [C-14]	2005	48	6	397–406
(<i>R</i>)-Etomidate, ([1-C-13] <i>O</i> -ethyl)	2004	47	11	723–731
F				
Fasidotril, [H-2] or [C-14] labelled	2004	47	14	1029–1033
Ferrocenes, [H-2], by acid-cat. hydrogen exchange	2005	48	3	209–218
Ferulic acid, [C-13] labelled	2004	47	11	797–806
<i>N</i> ^z -(9-Fluorenylmethoxycarbonyl)- <i>O</i> -(3,4,6-tri- <i>O</i> -acetyl-2-deoxy-2-fluoro- <i>D</i> -glucopyranosyl)-L-serine, [F-18]	2005	48	10	701–719
<i>N</i> ^z -(9-Fluorenylmethoxycarbonyl)- <i>O</i> -(3,4,6-tri- <i>O</i> -acetyl-2-deoxy-2-fluoro- <i>D</i> -glucopyranosyl)-L-threonine, [F-18]	2005	48	10	701–719
<i>N</i> -(4-Fluorobenzyl)-2-bromoacetamide, [F-18], in labelling of peptide nucleic acids	2005	48	1	51–61
4'-(4-Fluorobenzyl)piperidine, [2,3,5,6-H-2(4)], [α,α -H-2(2)] or [$\alpha,\alpha,2,3,5,6$ -H-2(6)]	2005	48	6	421–427
Fluorocyclophosphamide, [F-18]	2005	48	9	635–643
1-(2-Fluoroethyl)-4-(4-cyanophenoxy)methyl]piperidine, [F-18]	2005	48	8	547–555
<i>N</i> -(4-[F-18]-Fluorophenyl)indoles	2005	48	1	31–43
4-Fluorophenyltriphenylphosphonium cation, [F-18], as PET radioligand	2005	48	2	131–137
<i>N</i> -(3-Fluoropropyl)-2 β -carbomethoxy-3 β -(4-fluorophenyl)nortropane, [3-F-18(1)]	2005	48	6	463–471
3-Fluoropropyl tertiary amines, [F-18], from azetidinium methanesulfonates	2004	47	13	953–970
3-Fluoropropyl tosylate, [F-18]	2005	48	6	463–471
Fluoromethyl tosylate, [F-18], improved synthesis	2005	48	8	557–568
Formaldehyde, [C-11]	2005	48	8	577–587
Furan, [1,2,3,4-C-13(4)]	2005	48	2	117–121
G				
Gemifloxacin, [C-14]	2004	47	11	779–786

Compound	Year	Vol	Part	Pages
H				
Histamine isotopomers, [H-3], enzymatic synth of	2005	48	1	45–50
(-)-7'-Hydroxyabscisic acid, [5,8',8',8'-H-2(4)]	2005	48	6	435–445
Hydroxyacetonitrile, [C-13(2); N-15(1)]	2004	47	12	837–846
4-Hydroxycarbazole, [4b,5,6,7,8,8a-C-14(6)] or [H-2(4)]	2005	48	6	407–419
(2S)-7-Hydroxy-3-(4'-hydroxyphenyl)-4-methyl-2-(4''-[2'''-(1-piperidino)ethoxy]phenyl)-2H-1-(Ar-C-14(2))benzo-pyran	2004	47	11	741–752
17 α -Hydroxy-11 β -4-[(methyl-[C-11]),1-methylethylamino-phenyl]-17 α -(prop-1-ynyl)-esta-4,9-dien-3-one	2005	48	9	657–668
N-([ring-C-14] 4-Hydroxyphenyl)-2-[1,1-dioxide-3-oxo-1,2-benzisothiazole-2(3H)-yl]acetamide	2005	48	3	219–222
I				
Imexon, [C-14]	2005	48	3	165–170
4-Imino-1,3-diazabicyclo[3.1.0]hexan-2-one, [2-C-14]	2005	48	3	165–170
Indole, [C-13(6)]	2004	47	10	635–646
Iodoalkynes, [I-123], from K alkynyltrifluoroborates	2005	48	5	359–362
3-(4-Iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno-[3,4-c]pyridin-5-one, [I-123]	2005	48	2	101–108
3'-Iododiethylstilbestrol, [I-125]	2004	47	10	669–678
Iodo-rhTIMP-2, [I-123]	2005	48	5	387–396
Iridium complexes in directed deuteriations	2003	46	13	1191–1204
Ir-catalysed <i>ortho</i> -deuteration of aryl ketones	2005	48	5	317–322
Isoniazid, [Tc-99m]-labeled	2005	48	5	363–377
J				
K				
L				
Laevulinic acid, [I-C-14]	2004	47	10	627–634
L-Lysine, [4-C-13]	2004	47	11	787–795
L-Lysine-aflatoxin B ₁ , [5,5,6,6-H-2(4)]	2004	47	11	807–815
LY377604, [C-14(6)] or [H-2(4)]	2005	48	6	407–419
LY450108, [C-14] or [H-3]	2005	48	2	85–100
M				
[N-[2-[(2-Mercaptoethyl)amino]acetyl]-2-aminoethanethiolate] rhenium(V) oxide, [Re-186]	2004	47	11	753–761
3-[2-(4-Methoxybenzyloxy)ethyl]-2,2-dimethylcyclobutylethanone, [I-C-13]	2005	48	3	223–229
2-(N-([C-11]-Methyl)-4-aminophenyl)-6-hydroxybenzothiazole	2004	47	10	679–682
Methyl aryl ketones, base-catalysed [H-2] or [H-3] exchange upon,	2004	47	12	891–894
Methyl aryl sulfones, base-catalysed [H-2] or [H-3] exchange upon,	2004	47	12	881–889

Compound	Year	Vol	Part	Pages
3-([C-11]-Methyl)-benzaldehyde (<i>m</i> -tolualdehyde, [C-11])	2005	48	9	629–634
4-([C-11]-Methyl)-benzoic acid (<i>p</i> -toluic acid, [C-11]), and methyl ester	2005	48	9	629–634
1,1'-([C-11]-Methylene)-di-(2-naphthol)	2005	48	8	577–587
[<i>1S</i> -(1 α ,3 α ,4 β)]-9-[2-Methylene-4-(phenylmethoxy)-3-[(phenylmethoxy)methyl]-2-[[4-methoxyphenyl-(diphenyl)-methyl]amino]-6-methoxy-9 <i>H</i> -purine, [8-C-14]	2005	48	9	645–655
Methyl hydrazinocarbamate, [N-15(2)], hydrochloride	2004	47	12	837–846
Methyl iodide, [C-11]	2005	48	9	629–634
Methyl iodide, [C-11]	2005	48	9	657–668
([C-11]-Methyl) jasmonate	2005	48	5	379–386
4-([H-2(3)]-Methyl)-8-methyldecanal	2004	47	13	921–934
4-Methylphenol, [methyl-C-11] (<i>p</i> -cresol, [C-11])	2005	48	9	629–634
<i>N</i> -[3-(1-Methyl-4-piperidinyl)-1 <i>H</i> -pyrrolo [3,2- <i>b</i>]pyridin-5-yl]propanamide, [C-14]	2005	48	9	669–681
2-Methylpropan-2-ol, [2-C-11]	2004	47	11	763–777
Methyl triflate, [C-11]	2004	47	13	911–920
Methyl triflate, [C-11]	2005	48	9	657–668
Microwave induced deuterium exchange	2004	47	11	733–740
MON 37500, [C-13], [C-14] or [N-15]	2005	48	6	397–406

N

NIDA 522131, [F-18]	2004	47	13	947–952
Nitrogen heterocycles, [H-2] or [H-3] labelling of, Ir-catalysed	2005	48	1	75–84
4-Nitrophenylacetic acid, [<i>carboxyl</i> -C-13]	2005	48	3	231–233
2-Nitrotoluene, [methyl-C-11]	2005	48	9	629–634
NSAIDs, [H-3] labelled,	2005	48	8	569–576

O

(7 <i>E</i> ,9 <i>Z</i>)-Octadeca-7,9-dienoic acid, [9,10-H-2(2)]	2004	47	12	847–856
(<i>1S</i> ,2 <i>S</i>)-(1-Oxiranyl)-2-([<i>ring</i> -H-2(5)]phenylethyl)carbamic acid, <i>tert</i> -butyl ester	2005	48	3	179–193

P

Peptide nucleic acids, [F-18] labelling	2005	48	1	51–61
(-)-Phaseic acid, [7'-H-2(3)]	2005	48	6	435–445
Pinonaldehyde, [1-C-13]	2005	48	3	223–229
Pyridinium chloride, [1-H-2(1)] or [H-2(6)], <i>O</i> -demethylation and hydrogen isotope exchange by	2005	48	6	457–461
1-4-(Pyridin-2-yl)phenyl-5(<i>S</i>)-2,5-bis[<i>N</i> -(methoxycarbonyl)- <i>L</i> - <i>tert</i> -leucinyl]amino-4(<i>S</i>)-hydroxy-6-[<i>ring</i> -C-13(6)]phenyl-2-azahexane, <i>also</i> BMS-232632	2005	48	2	123–130

Compound	Year	Vol	Part	Pages
Q				
R				
Raman spectroscopy in the monitoring of [H-3] labeling	2004	47	13	983–995
[Re-186] complexes	2004	47	11	753–761
[Re-188] – (PhCS ₃) ₂ -PhCS ₂ labelled lipiodol	2004	47	12	857–867
Ro-647312, [C-11]	2004	47	13	911–920
RU40555, [C-11]	2005	48	9	657–668
S				
Saquinavir, [<i>ring</i> -H-2(5)]	2005	48	3	179–193
Sch 66336, [C-13(2), N-15(1)] or [H-3] or [C-14]	2005	48	1	11–23
Sinapic acid, [C-13]-labelled	2004	47	11	797–806
ST-1859, [C-11]	2005	48	8	577–587
T				
[Tc-99m]- <i>N</i> -(2,6-diisopropylchloroacetanilide)imino-diacetate	2004	47	10	683–697
[Tc-99m]-glucoheptonate	2004	47	10	683–697
[Tc-99m]-human serum albumin	2004	47	10	683–697
[Tc-99m]-isoniazid	2005	48	5	363–377
[Tc-99m]-methylene diphosphonate	2004	47	10	683–697
[Tc-99m]nitrido bis(<i>N</i> -cyclopentyl dithiocarbamate) complex	2004	47	10	647–655
[Tc-99m]-2,2,9,9-tetramethyl-4,7-diazadecane-1,2-dithiolate	2004	47	10	683–697
[Tc-99m]tricarbonyl complexes with MIBI, TBI, isoniazid or mebrotfenin	2004	47	10	657–668
[Tc-99m]tricarbonyl cysteine complex	2005	48	1	63–73
[Tc-99m]- <i>L-N</i> -(2-((2-(triphenylmethyl)thio)ethyl)amino)-acetyl)- <i>S</i> -(triphenylmethyl)-2-aminoethanethiolate	2004	47	10	683–697
[Tc-99m]-UBI 29-41, for specific infection detection	2005	48	9	683–691
1,3,4,6-Tetra- <i>O</i> -acetyl-2-deoxy-2-fluoro-D-glucopyranoside, [F-18]	2005	48	10	701–719
rhTIMP-2, [I-123]	2005	48	5	387–396
Toluenes, [7-C-11]	2005	48	9	629–634
<i>N</i> -3-(2-(<i>IR</i>)-1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy(3 <i>S</i> ,2 <i>R</i>)-3-(4-fluorophenyl)morpholin-4-yl)(1 <i>Z</i>)-2-([<i>N</i> -15(1)]-amino)-1-[<i>N</i> -15(1), C-13(2)]azaprop-1-enyl]methoxycarbonyl[<i>N</i> -15(1)]amide	2004	47	12	837–846
(2 <i>S</i>)-7-Trimethylacetoxy-3-(4'-trimethylacetoxyphenyl)-4-methyl-2-(4''-[2'''-(1-piperidino)ethoxy]phenyl)-2 <i>H</i> -1-([Ar-C-14(2)])benzo-pyran	2004	47	11	741–752
2,6,10-Trimethyl-2-dodecene, [12-H-2(3)]	2004	47	13	921–934
Tryptophan, [C-13(6)]	2004	47	10	635–646
<i>L</i> -Tyrosine, [2,6-H-3(2)]	2004	47	13	977–982

Compound		Year	Vol	Part	Pages
	U				
UBI 29-41, antimicrobial peptide, [Tc-99m] labelled		2005	48	9	683–691
	V				
Vinyl chloride, [C-14]		2004	47	13	903–910
	W				
	X				
	Y				
	Z				